RxDoctor Payments Data

Simon O Regan, MD

Family Medicine · Havelock, NCNPI 1538177100

Payments from drug & device makers

$257in general payments, 2019–2025

Across 14 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$85
  • Amgen$55
  • AbbVie$46
  • Pfizer$29
  • Abbott$24
  • Novo Nordisk$17

What the payments were for

  • Food & beverage$257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson4$85
Amgen3$55
AbbVie3$46
Pfizer2$29
Abbott1$24
Novo Nordisk1$17

How this compares

$257 in reported general payments places this provider in the 45th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$244,412
Medicare patients
435
Services billed
9,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$106,415
OzempicSemaglutide71$89,540
EliquisApixaban59$76,233
FarxigaDapagliflozin Propanediol38$41,822
XareltoRivaroxaban32$37,845
JanuviaSitagliptin Phosphate20$31,060
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$26,189
MyrbetriqMirabegron29$18,975
SymbicortBudesonide/Formoterol Fumarate45$18,426
LinzessLinaclotide23$16,827
MounjaroTirzepatide13$15,070
TradjentaLinagliptin18$14,191
Breo ElliptaFluticasone/Vilanterol32$13,427
DuleraMometasone/Formoterol22$10,598
Incruse ElliptaUmeclidinium Bromide16$7,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$89,54071 claims
PfizerEliquis, Dilantin$29$78,42471 claims
Johnson & JohnsonXarelto$85$37,84532 claims
AbbVieLinzess$46$16,82723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Havelock

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →